<DOC>
	<DOCNO>NCT02728518</DOCNO>
	<brief_summary>The investigator 's goal study evaluate efficacy safety nebulized amikacin versus intravenous amikacin patient hospital ventilator acquire pneumonia surgical patient admit intensive care unit infect gram negative bacillus</brief_summary>
	<brief_title>Nebulized Amikacin Versus Intravenous Amikacin Treatment Nosocomial Pneumonia</brief_title>
	<detailed_description>prospective , randomize , control study post-cardiac surgery patient , include two group , one year period . The first group administer intravenous ( IV ) amikacin 20 mg/kg daily . The second group prescribe amikacin nebulizer 400 mg twice daily . Both group co-administered intravenous ( IV ) piperacillin/tazobactam empirically .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Patients admit ICU Clinical suspicion VAP HAP define new persistent radiological infiltrate one follow sign : purulent tracheal aspiration , temperature 38Â° high , leucocyte count &gt; 10000/ml Positive culture sensitive amikacin In case empirical treatment , risk multi resistant bacteria define follow : Antimicrobial therapy precede 90 day Current hospitalization 5 History Asthma Multi organ failure psychiatric illness allergy amikacin intolerance nebulized amikacin Myasthenia gravis . Severely impaired renal function ( creatinine clearance lower 10 mL/min renal replacement therapy ) Vestibulocochlear disease . Pregnancy . Brain death</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>